KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Neogenomics (NEO) EPS (Weighted Average and Diluted) (2016 - 2026)

Neogenomics filings provide 16 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.13 for Q1 2026.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 35.0% to -$0.13 in Q1 2026 year-over-year; TTM through Mar 2026 was -$0.76, a 24.59% decrease, with the full-year FY2025 number at -$0.84, down 35.48% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.13 in Q1 2026 for Neogenomics, down from -$0.07 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.07 in Q4 2025 to a low of -$0.4 in Q1 2022.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.19 (2023), compared with a mean of -$0.2.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 147.46% in 2022 and later soared 50.0% in 2023.
  • Neogenomics' EPS (Weighted Average and Diluted) stood at -$0.18 in 2022, then surged by 38.89% to -$0.11 in 2023, then decreased by 9.09% to -$0.12 in 2024, then soared by 41.67% to -$0.07 in 2025, then crashed by 85.71% to -$0.13 in 2026.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.13 (Q1 2026), -$0.07 (Q4 2025), and -$0.21 (Q3 2025) per Business Quant data.